Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | FABP7 | O15540 | 1/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | FKBP1A | P62942 | 3/20 | 0.44 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.43 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.43 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2406746 | 1.00 | TSHR (0.51) | TSHRALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL25642133 | 1.00 | TSHR (0.51) | TSHRALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL26696686 | 1.00 | TSHR (0.51) | TSHRALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL5425578 | 1.00 | TSHR (0.51) | TSHRALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL8171037 | 0.91 | ALDH1A1 (0.50) | TSHRALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL18806518 | 0.91 | ALDH1A1 (0.50) | TSHRALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2299970 | 0.91 | ALDH1A1 (0.50) | TSHRALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL26255812 | 0.91 | ALDH1A1 (0.50) | TSHRALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL2299968 | 0.91 | ALDH1A1 (0.50) | TSHRALDH1A1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL15709940 | 0.91 | TSHR (0.56) | TSHRALDH1A1SMN1; SMN2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-11-02 | — | — | US | disclosed |
| US-11667602-B2 | Compounds and their use | ASTRAZENECA AB (SE) | 2023-06-06 | — | — | US | disclosed |
| US-20230078576-A1 | COMPOUNDS AND THEIR USE | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2023-03-16 | — | — | US | disclosed |
| EP-1805316-B1 | PROCESS FOR THE PREPARATION OF THE ENANTIOMERIC FORMS OF CIS-3-HYDROXYCYCLOHEXANE CARBOXYLIC ACID DERIVATIVES EMPLOYING HYDROLASES | SANOFI AVENTIS DEUTSCHLAND (DE) | 2009-04-15 | — | — | EP | disclosed |
| US-20070197788-A1 | METHOD FOR THE PREPARATION OF ENANTIOMER FORMS OF CIS-CONFIGURED 3-HYDROXYCYCLOHEXANE CARBOXYLIC ACID DERIVATIVES USING HYDROLASES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197788-A1 | METHOD FOR THE PREPARATION OF ENANTIOMER FORMS OF CIS-CONFIGURED 3-HYDROXYCYCLOHEXANE CARBOXYLIC ACID DERIVATIVES USING HYDROLASES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
| US-20070197788-A1 | METHOD FOR THE PREPARATION OF ENANTIOMER FORMS OF CIS-CONFIGURED 3-HYDROXYCYCLOHEXANE CARBOXYLIC ACID DERIVATIVES USING HYDROLASES | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-08-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11667602-B2 | Compounds and their use | RXFP1, RXFP3, RXFP2 | TSHR 436/4885ALDH1A1 1531/4885SMN1; SMN2 2080/4885 |
| US-20230348363-A1 | COMPOUNDS AND THEIR USE | RXFP1, RXFP3, RXFP2 | TSHR 436/4885ALDH1A1 1531/4885SMN1; SMN2 2080/4885 |
| US-20230078576-A1 | COMPOUNDS AND THEIR USE | RXFP1, RXFP3, RXFP2 | TSHR 436/4885ALDH1A1 1531/4885SMN1; SMN2 2080/4885 |
| US-20070197788-A1 | METHOD FOR THE PREPARATION OF ENANTIOMER FORMS OF CIS-CONFIGURED 3-HYDROXYCYCLOHEXANE CARBOXYLIC ACID DERIVATIVES USING HYDROLASES | CES1, COASY, CYP51A1 | TSHR 3448/4885ALDH1A1 304/4885SMN1; SMN2 3719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.